Management of cerebral small vessel disease for the diagnosis and treatment of dementia

Brain and Nerve

Volumn 65, Issue 7, 2013, Pages 801-809

  Ihara, Masafumi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Alzheimer's disease; Amyloid ; Arteriosclerosis; Cerebral amyloid angiopathy; Small vessel disease

Indexed keywords

AMYLOID BETA PROTEIN; VASOACTIVE AGENT;

ALZHEIMER DISEASE; ARTERIOSCLEROSIS; BRAIN BLOOD VESSEL; BRAIN CORTEX; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; HUMAN; IMMUNOTHERAPY; PARENCHYMA; REVIEW; RISK ASSESSMENT; UPREGULATION; VASCULAR AMYLOIDOSIS; VASCULAR DISEASE; WHITE MATTER;

AMYLOID BETA-PEPTIDES; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL SMALL VESSEL DISEASES; DEMENTIA; HUMANS;

EID: 84880435110     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO: Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 18: 253-266, 2008 (Pubitemid 351430402)
2. O'Brien C: Auguste D. and Alzheimer's disease. Science 273: 28, 1996
3. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, et al: Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 6: e1000180, 2009
4. Pantoni L: Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9: 689-701, 2010
5. Pantoni L, Garcia JH: The significance of cerebral white matter abnormalities 100 years after Binswanger's report: a review. Stroke 26: 1293-1301, 1995
6. Seines OA, Vinters HV: Vascular cognitive impairment. Nat Clin Pract Neurol 2: 538-547, 2006
7. Andin U, Gustafson L, Passant U, Brun A: A clinico-pathological study of heart and brain lesions in vascular dementia. Dement Geriatr Cogn Disord 19: 222-228, 2005 (Pubitemid 40522810)
8. Ihara M, Polvikoski TM, Hall R, Slade JY, Perry RH, et al: Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol 119: 579-589, 2010
9. Cordonnier C, Van der Flier WM, Sluimer JD, Leys D, Barkhof F, et al: Prevalence and severity of microbleeds in a memory clinic setting. Neurology 66: 1356-1360, 2006 (Pubitemid 43739644)
10. McCarron MO, Nicoll JAR: Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 3: 484-492, 2004 (Pubitemid 38903099)
11. Weller RO, Djuanda E, Yow HY, Carare RO: Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 117: 1-14, 2009
12. Okamoto Y, Ihara M, Fujita Y, Ito H, Takahashi R, et al: Cortical microinfarcts in Alzheimer's disease and subcortical vascular dementia. Neuroreport 20: 990-996, 2009
13. Haglund M, Sjobeck M, Englund E: Severe cerebral amyloid angiopathy characterizes an underestimated variant of vascular dementia. Dement Geriatr Cogn Disord 18: 132-137, 2004 (Pubitemid 39140362)
14. Smith EE, Greenberg SM: Beta-amyloid, blood vessels, and brain function. Stroke 40: 2601-2606, 2009
15. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, et al: Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383: 707-710, 1996 (Pubitemid 26360644)
16. Yamamoto Y, Ihara M, Tham C, Low RWC, Slade JY, et al: Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. Stroke 40: 2004-2011, 2009
17. Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, et al: Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 360: 1729-1739, 2009
18. Moody DM, Brown WR, Challa VR, Anderson RL: Periventricular venous collagenosis: association with leukoaraiosis. Radiology 194: 469-476, 1995
19. Kalaria RN, Akinyemi R, Ihara M: Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 322: 141-147, 2012
20. Viswanathan A, Rocca WA, Tzourio C: Vascular risk factors and dementia: how to move forward? Neurology 72: 368-374, 2009
21. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, et al: Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 42: 2672-2713, 2011
22. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, et al: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277: 813-817, 1997 (Pubitemid 27111317)
23. Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, et al: White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurology 70: 1-7, 2013
24. Gurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez-Ramirez S, et al: Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol 2012 Dec 13. doi: 10.1002/ana. 23830 [Epub ahead of print]
25. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study: Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357: 169-175, 2001
26. Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, et al: Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 33: 1986-1992, 2002 (Pubitemid 34840055)
27. Okamoto Y, Yamamoto T, Kalaria RN, Senzaki H, Maki T, et al: Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 123: 381-394, 2012
28. Westover MB, Bianchi MT, Yang C, Schneider JA, Greenberg SM: Estimating cerebral microinfarct burden from autopsy samples. Neurology 80: 1365-1369, 2013
29. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM: Cerebral microinfarcts: the invisible lesions. Lancet Neurol 11: 272-282, 2012
30. Brundel M, De Bresser J, Van Dillen JJ, Kappelle LJ, Biessels GJ: Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab 32: 425-436, 2012
31. Ii Y, Maeda M, Kida H, Matsuo K, Shindo A, et al: In vivo detection of cortical microinfarcts on ultrahigh-field MRI. J Neuroimaging 23: 28-32, 2013
32. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, et al: Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11: 241-249, 2012
33. Pluta R, Furmaga-Jabłońska W, Maciejewski R, Ułamek-Kozioł M, Jabłoński M: Brain ischemia activates β- and γ-secretase cleavage of amyloid precursor protein: significance in sporadic Alzheimer's disease. Mol Neurobiol 47: 425-434, 2013
34. Velliquette RA, O'Connor T, Vassar R: Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 25: 10874-10883, 2005 (Pubitemid 41692617)
35. Sun X, He G, Qing H, Zhou W, Dobie F, et al: Hypoxia facilitates Alzheimer's disease pathogenesis by upregulating BACE1 gene expression. Proc Natl Acad Sci U S A 103: 18727-18732, 2006 (Pubitemid 44913478)
36. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, et al: Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164: 719-725, 2004 (Pubitemid 38364685)
37. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, et al: Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 283: H315-H323, 2002 (Pubitemid 34705353)
38. Hawkes CA, Härtig W, Kacza J, Schliebs R, Weller RO, et al: Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol 121: 431-443, 2011
39. Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665, 2009
40. Barnes DE, Yaffe K: The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10: 819-828, 2011
41. Rovio S, Kåreholt I, Helkala E-L, Viitanen M, Winblad B, et al: Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 4: 705-711, 2005 (Pubitemid 41457285)
42. Deschaintre Y, Richard F, Leys D, Pasquier F: Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73: 674-680, 2009
43. Li N-C, Lee A, Whitmer RA, Kivipelto M, Lawler E, et al: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340: b5465, 2010
44. Hajjar I, Brown L, Mack WJ, Chui H: Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 69: 1632-1638, 2012
45. Fuentes B, Fernández-Domínguez J, Ortega-Casarrubios MÁ, SanJosé B, Martínez-Sánchez P, et al: Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction. J Hypertens 28: 575-581, 2010
46. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, et al: Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 358: 2787-2795, 2008 (Pubitemid 351930853)
47. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, et al: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9: 959-968, 2010
48. Arai H, Takahashi T: A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am J Geriatr Psychiatry 17: 353-354, 2009
49. Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, et al: Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study. Geriatr Gerontol Int 13: 90-97, 2013
50. Taguchi A, Takata Y, Ihara M, Kasahara Y, Tsuji M, et al: Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis. Psychogeriatrics, 2013 (in press)
51. Clin Neurosci 30: 1076, 2012
52. Fotuhi M, Hachinski V, Whitehouse PJ: Changing perspectives regarding late-life dementia. Nat Rev Neurol 5: 649-658, 2009